|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.97 USD | +0.18% |
|
+0.71% | +9.22% |
| 05-16 | Axonics Implant Approved in Australia to Treat Overactive Bladders | MT |
| 05-16 | Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia | CI |
Axonics, Inc. provided revenue guidance for 2023. For the period, Total company net revenue is expected to be $342 million, which is based on sacral neuromodulation and Bulkamid revenue each growing 25% compared to fiscal year 2022.
| 1st Jan change | Capi. | |
|---|---|---|
| +9.22% | 3.47B | |
| -1.72% | 12B | |
| -20.95% | 6.88B | |
| +58.12% | 6.86B | |
| -28.32% | 4.33B | |
| -17.21% | 2.54B | |
| -18.86% | 1.9B | |
| -28.80% | 1.58B | |
| -38.19% | 1.43B | |
| -15.36% | 1.08B |
AXONICS, INC. 
